<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03033602</url>
  </required_header>
  <id_info>
    <org_study_id>W81WH-15-1-0391</org_study_id>
    <nct_id>NCT03033602</nct_id>
  </id_info>
  <brief_title>Brief Treatment for Posttraumatic Stress Disorder</brief_title>
  <official_title>Brief Treatment for PTSD: Enhancing Retention and Engagement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston VA Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston VA Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to examine whether a brief treatment approach for PTSD is&#xD;
      equally efficacious in the treatment of active duty service members relative to a first line&#xD;
      treatment approach that requires much greater treatment dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this randomized clinical trial is to investigate if a brief, written intervention&#xD;
      for posttraumatic stress disorder (PTSD), Written Exposure Therapy (WET), is equally&#xD;
      efficacious as an evidenced-based behavioral therapy, Cognitive Processing Therapy-Cognition&#xD;
      only (CPT-C), in the treatment of PTSD in active duty military men and women with a diagnosis&#xD;
      of PTSD who have deployed in support of a post-9/11. The primary study outcome will be change&#xD;
      in symptom severity as assessed by the Clinician Administered PTSD Scale for Diagnostic and&#xD;
      Statistical Manual-5 edition (CAPS-5). Independent assessors will evaluate participants using&#xD;
      the CAPS-5 at baseline, 10- (post-treatment), 20-, and 30-week intervals after the start of&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2015</start_date>
  <primary_completion_date type="Actual">October 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Administered PTSD Scale, 5</measure>
    <time_frame>Change from baseline to 10-, 20-, 30-weeks post first treatment session</time_frame>
    <description>PTSD symptom scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>Written exposure therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 sessions of imaginal exposure therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CPT, cognitive only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 sessions of cognitive therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>written exposure therapy</intervention_name>
    <description>five sessions of writing about traumatic experience.</description>
    <arm_group_label>Written exposure therapy</arm_group_label>
    <other_name>WET</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CPT, cognitive only</intervention_name>
    <description>12 sessions of cognitive therapy related to traumatic experience.</description>
    <arm_group_label>CPT, cognitive only</arm_group_label>
    <other_name>CPT-C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female active duty military personnel who have deployed in support of a&#xD;
             post-9/11 conflict seeking treatment for PTSD&#xD;
&#xD;
          -  Diagnosis of PTSD&#xD;
&#xD;
          -  Ability to speak, read and write English&#xD;
&#xD;
          -  Not currently engaged in psychosocial treatment for PTSD&#xD;
&#xD;
          -  Individuals taking psychotropic medications agree to work with their prescriber to&#xD;
             remain on stable doses of any prescribed psychotropic medications for the duration of&#xD;
             the intervention and through the first follow-up assessment as much as possible and as&#xD;
             medically indicated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current suicide or homicide risk meriting crisis intervention&#xD;
&#xD;
          -  Active psychosis&#xD;
&#xD;
          -  Moderate to severe brain damage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Sloan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston VA Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ft. Hood</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center, San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

